Gonadotropin Releasing Hormone Agonist Treatment to Increase Final Stature in Children With Precocious Puberty: A Meta-Analysis
In the setting of central precocious puberty (CPP), the motivation for hormonal intervention is to help the child to reach a taller adult stature than she would achieve otherwise. While gonadotropin-releasing hormone analogs (GnRHa) constitute an established treatment for improving adult stature in...
| Main Authors: | , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Wolters Kluwer Health
2014
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4602779/ |
| Summary: | In the setting of central precocious puberty (CPP), the motivation for hormonal intervention is to help the child to reach a taller adult stature than she would achieve otherwise. While gonadotropin-releasing hormone analogs (GnRHa) constitute an established treatment for improving adult stature in girls presenting with CPP up to age 6 (true precocious puberty), it is not yet clear whether or not the same is true in the setting of CPP presented in girls beyond age 6 (advance puberty). GnRHa may slow growth velocity, offsetting the anticipated improvement in final height that should have resulted from the increased time before growth plate fusion. Consequently, it's been suggested that growth hormone (GH) should be combined with GnRHa to improve the results. |
|---|